Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bättig, Basil A
REDUSE, NCT02051218 / 2014-001189-87: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks	Active, not recruiting	3	1380	Europe	Denosumab (reduced dosing), XGEVA®, Denosumab (standard dosing)	Swiss Group for Clinical Cancer Research	Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases	06/26	12/28
OGIPRO, NCT05234021: HER2-directed Biosimilar in Breast Cancer: Real World ePRO	Completed	N/A	52	Europe		OnkoZentrum Zürich AG, University of Zurich, Palleos Healthcare GmbH	HER2-positive Breast Cancer, Biosimilar, Patient Reported Outcome	06/23	06/23